Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting BMD Z score \<-2 at the level of the femoral neck or of the lumbar column Regular transfusional regimen in order to mantain pre-transfusional Hb values \>9 g/dl.~Written informed consent by the patient~Exclusion Criteria:~Entravenous administration of bisphosphonates within the past 2 years~Administration of di bisphosphonates per os, unless wash out as it follows:~1 year if \>8 weeks \<48 weeks 6 months if \> 2 weeks and \<8 weeks Hypoparathyroidism Thalassemia Intermedia if not regularly transfused Pregnancy and breast feeding Impaired renal function (creat. \> 1.5 mg/dl) Neoplastic disease Patients with mean levels of alanine aminotransferase ALT \> 300 U/l and patients with variations of AST or AST of 300% within the year before randomization. (At least 4 misurations over 12 months) Systemic cardiovascular, renal, hepatic disease etc. which would prevent the patient from undergoing study treatment Known hypersensibility to bisphosphonates. History of non compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neridronato (Type: EXPERIMENTAL): Thalassemia Major or Severe Thalassemia Intermedia
- Placebo (Type: NO_INTERVENTION): Thalassemia Major or Severe Thalassemia Intermedia

Based on this trial design, predict the completion outcome and termination type (if applicable).